3 news items
MEI Pharma Aligns On Strategy To Advance Voruciclib And ME-344
MEIP
11 Apr 24
patients with colorectal cancer new treatment options in light of the fact that deaths from this disease are a leading cause of cancer-related deaths
MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344
MEIP
11 Apr 24
medical need to provide patients with colorectal cancer new treatment options in light of the fact that deaths from this disease are a leading cause
MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia
MEIP
26 Mar 24
prevent the cell from undergoing cell death. Inhibition of CDK9 blocks the production of Mcl-1, which is an established resistance mechanism to the B-cell
- Prev
- 1
- Next